Loi Mervin V, Lee Jan Hau, Huh Jimmy W, Mallory Palen, Napolitano Natalie, Shults Justine, Krawiec Conrad, Shenoi Asha, Polikoff Lee, Al-Subu Awni, Sanders Ronald, Toal Megan, Branca Aline, Glater-Welt Lily, Ducharme-Crevier Laurence, Breuer Ryan, Parsons Simon, Harwayne-Gidansky Ilana, Kelly Serena, Motomura Makoto, Gladen Kelsey, Pinto Matthew, Giuliano John, Bysani Gokul, Berkenbosch John, Biagas Katherine, Rehder Kyle, Kasagi Mioko, Lee Anthony, Jung Philipp, Shetty Rakshay, Nadkarni Vinay, Nishisaki Akira
Department of Pediatric Subspecialties, Children's Intensive Care Unit, KK Women's and Children's Hospital, 100 Bukit Timah Road, Singapore, Singapore.
Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Neurocrit Care. 2024 Feb;40(1):205-214. doi: 10.1007/s12028-023-01734-0. Epub 2023 May 9.
Ketamine has traditionally been avoided for tracheal intubations (TIs) in patients with acute neurological conditions. We evaluate its current usage pattern in these patients and any associated adverse events.
We conducted a retrospective observational cohort study of critically ill children undergoing TI for neurological indications in 53 international pediatric intensive care units and emergency departments. We screened all intubations from 2014 to 2020 entered into the multicenter National Emergency Airway Registry for Children (NEAR4KIDS) registry database. Patients were included if they were under the age of 18 years and underwent TI for a primary neurological indication. Usage patterns and reported periprocedural composite adverse outcomes (hypoxemia < 80%, hypotension/hypertension, cardiac arrest, and dysrhythmia) were noted.
Of 21,562 TIs, 2,073 (9.6%) were performed for a primary neurological indication, including 190 for traumatic brain injury/trauma. Patients received ketamine in 495 TIs (23.9%), which increased from 10% in 2014 to 41% in 2020 (p < 0.001). Ketamine use was associated with a coindication of respiratory failure, difficult airway history, and use of vagolytic agents, apneic oxygenation, and video laryngoscopy. Composite adverse outcomes were reported in 289 (13.9%) Tis and were more common in the ketamine group (17.0% vs. 13.0%, p = 0.026). After adjusting for location, patient age and codiagnoses, the presence of respiratory failure and shock, difficult airway history, provider demographics, intubating device, and the use of apneic oxygenation, vagolytic agents, and neuromuscular blockade, ketamine use was not significantly associated with increased composite adverse outcomes (adjusted odds ratio 1.34, 95% confidence interval CI 0.99-1.81, p = 0.057). This paucity of association remained even when only neurotrauma intubations were considered (10.6% vs. 7.7%, p = 0.528).
This retrospective cohort study did not demonstrate an association between procedural ketamine use and increased risk of peri-intubation hypoxemia and hemodynamic instability in patients intubated for neurological indications.
传统上,急性神经系统疾病患者进行气管插管时应避免使用氯胺酮。我们评估了其在这些患者中的当前使用模式以及任何相关不良事件。
我们对53个国际儿科重症监护病房和急诊科中因神经科指征接受气管插管的危重症儿童进行了一项回顾性观察队列研究。我们筛查了2014年至2020年录入多中心国家儿童紧急气道登记处(NEAR4KIDS)登记数据库的所有插管记录。纳入年龄在18岁以下且因主要神经科指征接受气管插管的患者。记录使用模式和报告的围手术期综合不良结局(低氧血症<80%、低血压/高血压、心脏骤停和心律失常)。
在21562次气管插管中,2073次(9.6%)是因主要神经科指征进行的,其中创伤性脑损伤/创伤190次。495次气管插管(23.9%)的患者使用了氯胺酮,其比例从2014年的10%增至2020年的41%(p<0.001)。氯胺酮的使用与呼吸衰竭、困难气道史、使用抗迷走神经药物、窒息氧合和视频喉镜检查的合并指征相关。289次(13.9%)气管插管报告了综合不良结局,在氯胺酮组更常见(17.0%对13.0%,p=0.026)。在对地点、患者年龄和合并诊断、呼吸衰竭和休克的存在、困难气道史、医疗人员特征、插管设备以及窒息氧合、抗迷走神经药物和神经肌肉阻滞剂的使用进行校正后,氯胺酮的使用与综合不良结局增加无显著相关性(校正比值比1.34,95%置信区间CI 0.99-1.81,p=0.057)。即使仅考虑神经创伤插管,这种相关性也不显著(10.6%对7.7%,p=0.528)。
这项回顾性队列研究未显示在因神经科指征插管的患者中,术中使用氯胺酮与插管周围低氧血症和血流动力学不稳定风险增加之间存在关联。